产品
编 号：F167899
分子式：C26H44NNaO7S
分子量：537.68
分子式：C26H44NNaO7S
分子量：537.68
产品类型
规格
价格
是否有货
500mg
560
In-stock
1g
640
In-stock
5g
询价
询价
结构图
CAS No: 145-42-6
产品详情
生物活性：
Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect.
体内研究：
Taurocholic acid (oral gavage, 100 mg/kg, 2 weeks) sodium 可降低 C57BL/6 小鼠 (尾静脉注射 rAAV8-1.3HBV) 中 NK 和 CD3+CD8+ T 细胞的百分比来促进 HBV 复制。Taurocholic acid (饮食中 1%，1 周) sodium通过上调 VEGF-A 表达来阻止肝动脉结扎 (HAL) 诱导的胆管细胞损伤。Animal Model:C57BL/6 mice
Dosage:100-mg/kg
Administration:oral gavage, for 2 weeks after tail vein injection with rAAV8-1.3HBV for 6 weeks
Result:Reduced the percentage of NK and CD3+CD8+ T cells.Increases serum HBsAg, HBeAg, and HBV DNA levels.
体外研究：
Taurocholic acid (100 μM, 24 h) sodium 可降低 HBeAg 阳性 CHB 患者分离的 PBMC 中 CD3+CD8+ T 和 NK 细胞的比例。Taurocholic acid (100 μM, 24 h) sodium 可降低 CD3+CD8+ T 和 NK 细胞中 IFN-α 刺激的细胞因子和细胞毒性颗粒水平(IFN-γ、TNF-α、颗粒酶 B) .
Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect.
体内研究：
Taurocholic acid (oral gavage, 100 mg/kg, 2 weeks) sodium 可降低 C57BL/6 小鼠 (尾静脉注射 rAAV8-1.3HBV) 中 NK 和 CD3+CD8+ T 细胞的百分比来促进 HBV 复制。Taurocholic acid (饮食中 1%，1 周) sodium通过上调 VEGF-A 表达来阻止肝动脉结扎 (HAL) 诱导的胆管细胞损伤。Animal Model:C57BL/6 mice
Dosage:100-mg/kg
Administration:oral gavage, for 2 weeks after tail vein injection with rAAV8-1.3HBV for 6 weeks
Result:Reduced the percentage of NK and CD3+CD8+ T cells.Increases serum HBsAg, HBeAg, and HBV DNA levels.
体外研究：
Taurocholic acid (100 μM, 24 h) sodium 可降低 HBeAg 阳性 CHB 患者分离的 PBMC 中 CD3+CD8+ T 和 NK 细胞的比例。Taurocholic acid (100 μM, 24 h) sodium 可降低 CD3+CD8+ T 和 NK 细胞中 IFN-α 刺激的细胞因子和细胞毒性颗粒水平(IFN-γ、TNF-α、颗粒酶 B) .
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备